Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Prolia (denosumab by Quarter
Prolia (denosumab — Postmenopausal Osteoporosis) — Worldwide net selling price change YoY (%) (%)
Amgen Prolia (denosumab: -12.0% in Q2 2026.
Latest, Q2 2026
-12.0%
Period ended Jun 30, 2026
Change on a year earlier
–
History
4 quarters
Since Q1 2025
Sources
4
Documents cited below
Where the Q2 2026 figure comes from
“Prolia ® (denosumab) sales decreased 32% year-over-year to $759 million in the second quarter, driven by 20% lower volume and 12% lower net selling price as multiple biosimilars have launched globally with more biosimilars expected.”
Source: Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Reported in Form 8-K Product Sales Performance & Form 10-Q / 10-K MD&A.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Prolia (denosumab — Postmenopausal Osteoporosis) — Worldwide net selling price change YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | -12.0% | – | Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | -10.0% | -5.0 pts | Form 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗ |
| Q4 2025 | Dec 31, 2025 | -8.0% | – | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
| Q1 2025 | Mar 31, 2025 | -5.0% | – | Form 8-K (amgn-20250331earningsrelea.htm, filed 2025-05-01) ↗ |
Cite this data
StockData. (2026). Amgen Prolia (denosumab (%), quarterly Q1 2025–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-prolia-price
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.